| 747 |
Centers for Disease Control and Prevention |
Html |
en |
Outbreak of Escherichia coli O104:H4 Infections Associatedwith Sprout Consumption - Europe and North America, May-July2011 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| outbreak vehicle | 0.345529 |
| robust public health | 0.411199 |
| Foodborne Outbreak Listserv | 0.418584 |
| Shiga toxin | 0.359822 |
| raw sprouts | 0.325763 |
| Escherichia coli | 0.365278 |
| public health authorities | 0.516905 |
| German HUS patients | 0.362963 |
| U.S. Department | 0.340705 |
| Health Alert Network | 0.326736 |
| STEC diagnostic testing | 0.450257 |
| Shiga toxin–positive stool | 0.331072 |
| outbreak management | 0.347476 |
| outbreak | 0.590926 |
| foodborne disease surveillance | 0.328541 |
| novel STEC pathogens | 0.522365 |
| non-O157 illness-causing STEC | 0.453281 |
| traceback investigations | 0.405795 |
| German public health | 0.350442 |
| laboratory-confirmed STEC infections | 0.447817 |
| World Health Organization | 0.331356 |
| Shiga toxin–positive specimens | 0.32799 |
| STEC outbreak worldwide | 0.562952 |
| state public health | 0.342271 |
| public health laboratories | 0.403645 |
|
| International Health Regulations | 0.331584 |
| new cases | 0.332476 |
| Germany | 0.326181 |
| public health infrastructure | 0.482923 |
| outbreak pathogens | 0.362877 |
| Shiga toxin–positive diarrheal | 0.344198 |
| United States | 0.785287 |
| hemolytic uremic syndrome | 0.387413 |
| STEC O104 | 0.930263 |
| non-O157 STEC | 0.538006 |
| U.S. cases | 0.33411 |
| public health | 0.75801 |
| outbreak strain | 0.462891 |
| Enteroaggregative STEC O104 | 0.504362 |
| cases | 0.432546 |
| STEC testing recommendations | 0.508094 |
| HUS | 0.378674 |
| STEC diarrheal illness | 0.504688 |
| HUS cases | 0.350066 |
| Robert Koch Institute | 0.391968 |
| raw fenugreek sprouts | 0.433152 |
| large outbreak | 0.345798 |
| STEC O157 | 0.464461 |
| food consumption commonalities | 0.331115 |
|
CLICK HERE |
| 4736 |
Centers for Disease Control and Prevention |
Html |
en |
Eastern Equine Encephalitis - Arboviral Diagnostic Testing |
Eastern Equine Encephalitis is a rare disease that is caused by a virus spread by infected mosquitoes.
|
| arbovirus activity increases | 0.755158 |
| initial results | 0.475105 |
| fatal cases | 0.479542 |
| CDC | 0.320276 |
| histopathology | 0.268133 |
| Microsphere-Based Immunoassay | 0.466658 |
| confirmatory testing | 0.443563 |
| virus-specific IgM | 0.598843 |
| APPROPRIATE STATE HEALTH | 0.644131 |
| final results | 0.447749 |
| state health department | 0.94534 |
| patient | 0.280121 |
| specimen receipt | 0.511579 |
| CSF | 0.299929 |
| Initial serological testing | 0.710934 |
| Laboratory diagnosis | 0.477449 |
| antibodies | 0.257283 |
| nucleic acid amplification | 0.723214 |
| immunohistochemistry | 0.268758 |
| area | 0.24686 |
| arboviral infections | 0.538003 |
|
| test results | 0.651322 |
| MIA | 0.251833 |
| epidemiologic history | 0.522521 |
| dates | 0.247121 |
| Instructions | 0.241315 |
| virus culture | 0.462514 |
| autopsy tissues | 0.502588 |
| DVBID Arbovirus Diagnostic | 0.798779 |
| hard copy | 0.441693 |
| Preliminary diagnosis | 0.501719 |
| places | 0.247164 |
| IgM capture ELISA | 0.78432 |
| diagnostic specimens | 0.457961 |
| activities | 0.246795 |
| location | 0.246642 |
| IgG ELISA | 0.530671 |
| state laboratories | 0.471293 |
| serum | 0.27277 |
| travel | 0.247077 |
| non-endemic country | 0.490728 |
|
CLICK HERE |
| 4823 |
Centers for Disease Control and Prevention |
Html |
en |
Upstream ecological risks for overweight and obesity among African American youth in a rural town in the Deep South, 2007 |
null |
| high school | 0.671122 |
| school board member | 0.570448 |
| ecological theory | 0.560775 |
| multiple ecological levels | 0.557328 |
| local high school | 0.517367 |
| in-depth interviews | 0.530755 |
| issues | 0.524764 |
| recreational center | 0.522832 |
| complex community contexts | 0.556882 |
| youth resource center | 0.52676 |
| African American student | 0.545668 |
| rural community settings | 0.53977 |
| community coalition members | 0.536659 |
| right social connections | 0.543378 |
| African American families | 0.537743 |
| white community members | 0.605576 |
| community | 0.831912 |
| upstream ecological factors | 0.568684 |
| embodiment theory | 0.584683 |
| African American teachers | 0.548252 |
| specific rural communities | 0.524595 |
| specific community contexts | 0.673013 |
| qualitative community health | 0.557917 |
| African American students | 0.546638 |
| rural town | 0.548008 |
|
| African American children | 0.534995 |
| African American pastor | 0.542716 |
| African American members | 0.555722 |
| Georgia Southern University | 0.612882 |
| white American populations | 0.534485 |
| local health department | 0.517281 |
| African American community | 0.731071 |
| larger community health | 0.550864 |
| American community members | 0.648857 |
| participants | 0.674353 |
| African American women | 0.534257 |
| rural youth | 0.522121 |
| African American representative | 0.546315 |
| rural communities | 0.540218 |
| race | 0.5435 |
| community organizations | 0.535061 |
| Deep South | 0.64514 |
| rural community | 0.572343 |
| African American youth | 0.984297 |
| physical activity | 0.541702 |
| community health assessment | 0.623387 |
| illegal drug activity | 0.551447 |
| upstream levels | 0.530593 |
| healthful food options | 0.556908 |
|
CLICK HERE |
| 8275 |
Centers for Disease Control and Prevention |
Html |
en |
Preventing Chronic Disease | Recruitment and Retention ofPregnant Women for a Behavioral Intervention: Lessons from theMaternal Adiposity, Metabolism, and Stress MAMAS Study -CDC |
Recruiting participants for research studies can be challenging. Many studies fall short of their target or must prolong recruitment to reach it. We examined recruitment and retention strategies and report lessons learned in a behavioral intervention developmental trial to encourage healthy pregnancy weight gain and stress reduction in low-income overweight pregnant women. |
| francisco bay area | 0.679178 |
| study participants | 0.651465 |
| healthy pregnancy weight | 0.646725 |
| prenatal behavioral intervention | 0.627398 |
| child care costs | 0.624855 |
| pregnancy weight gain | 0.649335 |
| low-income study participants | 0.649307 |
| hospital-based prenatal clinics | 0.870349 |
| pregnant women | 0.948162 |
| recruitment | 0.717647 |
| clinic staff | 0.678502 |
| recruit low-income women | 0.640665 |
| gestational age | 0.711307 |
| social service providers | 0.623704 |
| San Francisco Bay | 0.67946 |
| 8-week behavioral intervention | 0.621619 |
| behavioral intervention | 0.676379 |
| low-income women | 0.688738 |
| stage pregnant women | 0.663755 |
| intervention participants | 0.651081 |
| California Pacific Medical | 0.618365 |
| intervention | 0.71233 |
| obese women | 0.631784 |
| study | 0.738022 |
| Phase | 0.662909 |
|
| Introduction
Recruiting participants | 0.630155 |
| weight gain | 0.679954 |
| intervention developmental trial | 0.621679 |
| gestational weight gain | 0.62321 |
| child care | 0.714388 |
| 8-week intervention | 0.618669 |
| social services agencies | 0.651552 |
| focus groups | 0.683691 |
| overall study retention | 0.614736 |
| eligible women | 0.855719 |
| intervention development trial | 0.6232 |
| eligible participants | 0.636194 |
| federal poverty guidelines | 0.674974 |
| prenatal care providers | 0.720656 |
| social services providers | 0.620009 |
| low-income minority women | 0.620264 |
| annual household income | 0.668159 |
| group intervention | 0.619645 |
| focus group participants | 0.740486 |
| inflexible work schedules | 0.613027 |
| San Francisco | 0.727267 |
| overweight pregnant women | 0.718981 |
| obese pregnant women | 0.868419 |
| retention rates | 0.65285 |
|
CLICK HERE |
| 8764 |
Centers for Disease Control and Prevention |
Html |
en |
Prevention and Control of Influenza with Vaccines: InterimRecommendations of the Advisory Committee on Immunization PracticesACIP, 2013 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| ACIP influenza | 0.872596 |
| currently available influenza | 0.481444 |
| influenza vaccination recommendation | 0.516999 |
| trivalent influenza vaccine | 0.570866 |
| Influenza Div | 0.356053 |
| Routine annual influenza | 0.493014 |
| inactivated influenza vaccines | 0.555669 |
| ACIP influenza recommendation | 0.677909 |
| Immunization Practices | 0.331406 |
| cell culture-based vaccine | 0.305035 |
| newly licensed influenza | 0.463795 |
| Influenza Vaccine Abbreviations | 0.575174 |
| advisory committee | 0.383121 |
| recommendation statement | 0.212496 |
| influenza vaccine | 0.782048 |
|
| trivalent inactivated influenza | 0.458233 |
| Vaccine Recommendations | 0.285925 |
| influenza season | 0.497059 |
| influenza vaccines | 0.931059 |
| ACIP influenza vaccination | 0.813065 |
| influenza vaccination statement | 0.493736 |
| ACIP influenza recommendations | 0.714686 |
| hemagglutinin influenza vaccine | 0.562011 |
| vaccine categories | 0.210027 |
| ACIP recommendations | 0.314726 |
| inactivated influenza vaccine | 0.572555 |
| U.S. vaccine abbreviations | 0.307242 |
| attenuated influenza vaccine | 0.56412 |
| influenza virus | 0.356037 |
|
CLICK HERE |
| 9176 |
Centers for Disease Control and Prevention |
Html |
en |
Prostate Cancer Rates by Race and Ethnicity |
Prostate cancer statistics from CDC: incidence and mortality by race and ethnicity. |
| numbers | 0.421228 |
| invasive cancer sites | 0.598755 |
| NVSS | 0.424124 |
| cancer excludes basal | 0.603825 |
| genital organs | 0.500593 |
| number | 0.463046 |
| shows | 0.46358 |
| ethnic populations | 0.601836 |
| A/PI | 0.419389 |
| Asian/Pacific Islander men | 0.601713 |
| registry-specific data quality | 0.585333 |
| prostate cancer incidence | 0.680285 |
| highest rate | 0.519055 |
| Hispanic origin | 0.601906 |
| National Vital Statistics | 0.574286 |
| Behavior recode | 0.508481 |
| National Program | 0.502499 |
| incidence rate | 0.639841 |
| age groups | 0.601885 |
| Sources | 0.419304 |
| graph | 0.470666 |
| Census P25–1130 | 0.604088 |
| population coverage | 0.602983 |
| data quality | 0.590945 |
| persons | 0.477805 |
|
| situ cancers | 0.502546 |
| death rates | 0.658072 |
| U.S. standard population | 0.7643 |
| AI/AN | 0.419413 |
| ethnicity | 0.484815 |
| 100,000 | 0.462855 |
| skin | 0.43263 |
| USCS technical notes | 0.938698 |
| data quality criteria | 0.58474 |
| cancer registries | 0.606121 |
| potential differences | 0.596273 |
| Asian/Pacific Islander | 0.633069 |
| †Race categories | 0.599682 |
| *Rates | 0.437861 |
| National Cancer Institute | 0.607294 |
| caution | 0.509713 |
| disease | 0.421074 |
| black men | 0.583168 |
| urinary bladder | 0.501382 |
| End Results program | 0.595054 |
| squamous cell carcinomas | 0.597043 |
| U.S. population | 0.59581 |
| prostate cancer | 0.907235 |
| American Indian/Alaska Native | 0.795329 |
|
CLICK HERE |
| 10117 |
Centers for Disease Control and Prevention |
Html |
en |
Vaccine Information Statement: Td (Tetanus, Diphtheria) - Vaccines - CDC |
Td (Tetanus Diphtheria) VIS |
| Compensation Program | 0.270031 |
| Vaccine Safety site | 0.45778 |
| Severe Problems | 0.327061 |
| vision changes | 0.279461 |
| Page | 0.342196 |
| painful muscle | 0.291177 |
| National Vaccine Injury | 0.447483 |
| tetanus | 0.39162 |
| unusual behavior | 0.274297 |
| nearest hospital | 0.275992 |
| severe allergies | 0.332716 |
| severe allergic reaction | 0.773582 |
| heart failure | 0.284673 |
| fast heartbeat | 0.277368 |
| Mild Problems | 0.284832 |
| severe allergy | 0.33121 |
| Vaccine Adverse Event | 0.451828 |
| usual activities | 0.277895 |
| Tetanus-causing bacteria | 0.290682 |
| VAERS website | 0.289389 |
| life-threatening allergic reaction | 0.383761 |
| booster dose | 0.283743 |
| person | 0.360024 |
| severe complications | 0.347153 |
| previous dose | 0.284358 |
|
| difficulty breathing | 0.27198 |
| breathing problems | 0.284431 |
| vaccination | 0.281763 |
| VICP website | 0.273198 |
| United States | 0.380659 |
| vaccines | 0.312574 |
| medical advice | 0.276654 |
| best medical care | 0.359471 |
| remote chance | 0.274477 |
| state health department | 0.339836 |
| medical attention | 0.338306 |
| vaccine package insert | 0.457301 |
| Current Edition Date | 0.373176 |
| diphtheria | 0.397539 |
| dirty wound | 0.283505 |
| Td vaccine | 0.921304 |
| time limit | 0.273637 |
| Mild fever | 0.286146 |
| severe pain | 0.386836 |
| people | 0.347813 |
| certain vaccines | 0.283137 |
| medical procedure | 0.277697 |
| doctor | 0.284351 |
| federal program | 0.272155 |
|
CLICK HERE |
| 11299 |
Centers for Disease Control and Prevention |
Html |
en |
What U.S. Hospitals Need to Know to Prepare for Ebola Virus Disease - Conference Call August 5, 2014 | Clinicians Outreach and Communication Activity (COCA) |
CDC Clinician Outreach and Communication Activity (COCA). Providing clinicians the most current and reliable information on emerging public health threats, such as pandemics, natural disasters, and bioterrorism. |
| impacted countries | 0.485042 |
| United States | 0.444016 |
| patients | 0.326601 |
| Ebola hemorrhagic fever | 0.809932 |
| U.S. hospitals | 0.457057 |
| updates | 0.323667 |
| steps | 0.331951 |
| American citizens | 0.454404 |
| COCA | 0.348577 |
|
| guidance | 0.329852 |
| recent Ebola virus | 0.821637 |
| West Africa | 0.551427 |
| U.S. healthcare facilities | 0.549834 |
| outbreak | 0.402273 |
| clinicians | 0.339802 |
| U.S. hospital | 0.433922 |
| possibility | 0.387737 |
|
CLICK HERE |
| 12085 |
Centers for Disease Control and Prevention |
Html |
en |
Healthy Places - Recent Accomplishments - Healthy Community Design Data |
Designing and Building Healthy Places |
| Travel Survey data | 0.65619 |
| potential health effects | 0.714037 |
| health impact assessment | 0.718178 |
| health impact | 0.807927 |
| unhealthy air quality | 0.660423 |
| health disparities | 0.639548 |
| bicycling routes | 0.61182 |
| pedestrian crossing islands | 0.733515 |
| positive health outcomes | 0.714705 |
| transportation modeling techniques | 0.663586 |
| busy street crossings | 0.657354 |
| transportation systems | 0.619605 |
| adverse birth outcomes | 0.672122 |
| scale design interventions | 0.692549 |
| Community Design Initiative | 0.653302 |
| Enhanced pedestrian crossing | 0.728271 |
| community design | 0.656001 |
| traditional public health | 0.710544 |
| Health Tool | 0.633194 |
| HIA data | 0.620338 |
| annual medical cost | 0.673165 |
| health criteria | 0.626535 |
| American Planning Association | 0.642461 |
| times more pedestrian | 0.65527 |
|
| health care utilization | 0.711235 |
| specialized surface treatments | 0.657192 |
| transportation infrastructure | 0.607046 |
| United States | 0.65964 |
| adverse health outcomes | 0.723539 |
| adverse health effects | 0.729804 |
| Physical Activity Guidelines | 0.713585 |
| Metropolitan Planning Organization | 0.641446 |
| physical activity.2 | 0.615112 |
| public health | 0.739708 |
| potential public health | 0.715002 |
| regional comprehensive plans | 0.640442 |
| bicyclist fatalities | 0.607719 |
| pedestrian bridges | 0.643395 |
| high school students | 0.674671 |
| physical activity | 0.964527 |
| pedestrian crossing signals | 0.868926 |
| commonly reported form | 0.664088 |
| National Park Service | 0.640571 |
| transportation planning | 0.620292 |
| health-promotive built environment | 0.651989 |
| Health impact assessments | 0.703604 |
| Phys Act Health. | 0.646091 |
| Health Workbook | 0.630877 |
|
CLICK HERE |
| 13230 |
Centers for Disease Control and Prevention |
Html |
en |
Decrease in Rate of Opioid Analgesic Overdose Deaths -Staten Island, New York City, 2011-2013 |
Denise Paone, EdD1, Ellenie Tuazon, MPH1, Jessica Kattan, MD1, Michelle L. Nolan, MPH1, Daniella Bradley O'Brien1, Deborah Dowell, MD2, Thomas A. Farley, MD3, Hillary V. |
| Staten Island prescribers | 0.469775 |
| overdose rates | 0.393587 |
| public health interventions | 0.509204 |
| analgesic–involved overdose mortality | 0.494321 |
| Prescription Monitoring Program | 0.383121 |
| state prescription monitoring | 0.433457 |
| Staten Island–specific | 0.382075 |
| heroin-involved overdose mortality | 0.401298 |
| New York City | 0.413413 |
| analgesic high-dose prescribing | 0.377967 |
| Staten Island rates | 0.425924 |
| Staten Island | 0.907289 |
| analgesic prescribing patterns | 0.376389 |
| overdose mortality rates | 0.537077 |
| opioid analgesic–involved mortality | 0.464188 |
| heroin-involved overdose deaths | 0.414935 |
| opioid analgesic mortality | 0.488139 |
| high-dose opioid | 0.443528 |
| high dose prescriptions | 0.382334 |
| overdose death rate | 0.414324 |
| opioid analgesic–involved overdose | 0.700631 |
| Island local news | 0.366255 |
| unintentional drug poisoning | 0.390769 |
| Staten Island physicians | 0.430353 |
|
| NYC boroughs | 0.428123 |
| opioid analgesic prescriptions | 0.677705 |
| Methadone-involved overdose deaths | 0.395821 |
| opioid analgesics | 0.515867 |
| short-acting opioid analgesic | 0.479745 |
| Staten Island stakeholders | 0.442052 |
| office educational visits | 0.426119 |
| Staten Island mortality | 0.467856 |
| judicious opioid prescribing | 0.461141 |
| opioid use disorders | 0.42855 |
| Staten Island–targeted efforts | 0.418692 |
| overdose mortality | 0.610933 |
| new york state | 0.387518 |
| opioid prescribing guidelines | 0.505838 |
| Staten Island town | 0.442758 |
| public service announcements | 0.388843 |
| analgesic prescribing data | 0.386709 |
| Staten Island campaign | 0.442581 |
| analgesic–involved overdose deaths | 0.434923 |
| Staten Island area | 0.414583 |
| overdose mortality trends | 0.412818 |
| Staten Island residents | 0.536873 |
| drug-involved overdose deaths | 0.391229 |
|
CLICK HERE |